Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Return on Capital Employed data on record, last reported at 0.16% in Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 8.0% year-over-year to 0.16%; the TTM value through Dec 2025 reached 0.16%, up 8.0%, while the annual FY2025 figure was 0.14%, 9.0% up from the prior year.
  • Return on Capital Employed reached 0.16% in Q4 2025 per LCTX's latest filing, up from 0.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.16% in Q4 2025 and bottomed at 0.44% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.24% recorded in 2024.
  • The widest YoY moves for Return on Capital Employed: up 8bps in 2025, down -17bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.22% in 2021, then grew by 4bps to 0.21% in 2022, then plummeted by -39bps to 0.29% in 2023, then increased by 18bps to 0.24% in 2024, then skyrocketed by 33bps to 0.16% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.16% in Q4 2025, 0.44% in Q3 2025, and 0.39% in Q2 2025.